Omeros Corporation (NASDAQ:OMER) shares saw an uptick in trading volume on Thursday . 1,116,012 shares traded hands during mid-day trading, an increase of 200% from the previous session’s volume of 371,756 shares.The stock last traded at $11.54 and had previously closed at $12.87.

A number of brokerages have recently weighed in on OMER. Maxim Group began coverage on shares of Omeros Corporation in a report on Saturday, June 4th. They issued a “buy” rating on the stock. Wedbush reaffirmed an “outperform” rating and issued a $56.00 target price on shares of Omeros Corporation in a research report on Thursday. WBB Securities reaffirmed a “buy” rating and issued a $75.00 target price on shares of Omeros Corporation in a research report on Tuesday, June 14th. Cantor Fitzgerald assumed coverage on shares of Omeros Corporation in a research report on Thursday, June 2nd. They issued a “buy” rating and a $21.00 target price on the stock. Finally, Zacks Investment Research downgraded shares of Omeros Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, July 13th. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $36.33.

The firm’s market cap is $444.96 million. The stock has a 50-day moving average of $11.42 and a 200 day moving average of $12.20.

Omeros Corporation (NASDAQ:OMER) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.18. During the same period in the previous year, the firm posted ($0.44) earnings per share. The firm had revenue of $10 million for the quarter, compared to analyst estimates of $9.80 million. The company’s revenue for the quarter was up 212.5% on a year-over-year basis. On average, analysts anticipate that Omeros Corporation will post ($1.70) earnings per share for the current fiscal year.

In other news, VP Marcia S. Kelbon sold 15,900 shares of the business’s stock in a transaction on Friday, July 15th. The shares were sold at an average price of $11.50, for a total transaction of $182,850.00. Following the transaction, the vice president now directly owns 179,497 shares of the company’s stock, valued at $2,064,215.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

A hedge fund recently raised its stake in Omeros Corporation stock. Nationwide Fund Advisors boosted its position in Omeros Corporation (NASDAQ:OMER) by 183.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 69,700 shares of the biopharmaceutical company’s stock after buying an additional 45,145 shares during the period. Nationwide Fund Advisors owned about 0.18% of Omeros Corporation worth $1,096,000 at the end of the most recent reporting period.

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.